Phase II Study of LY353381-HC1 Administered to Women With Refractory Ovarian Cancer

Next Previous
Trial Profile

Phase II Study of LY353381-HC1 Administered to Women With Refractory Ovarian Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2012

At a glance

  • Drugs Arzoxifene (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 17 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top